Future of Depomed | Quantumrun

Future of Depomed

The Depomed, Inc. corporation is a U.S. based specialty pharmaceutical business, which chiefly deals in marketing of products for the treatment of pain, neurology, and illnesses relating to the central nervous system. The organization was originally founded in the year 1995 and has its headquarters based in Newark, California. This is a public trading company with numerous manufactured goods appropriated by the (FDA) or the United States Food and Drug Administration.

Home Country: 
United States
Industry: 
Pharmaceutical
Industry vulnerability to disruption: 

<p>Belonging to the pharmaceuticals sector means this company will be affected directly and indirectly by a number of disruptive opportunities and challenges over the coming decades. While described in detail within Quantumrun’s special reports, these disruptive trends can be summarized along the following broad points:</p>

<p>*First off, the late 2020s will see the Silent and Boomer generations enter deep into their senior years. Representing nearly 30-40 per cent of the global population, this combined demographic will represent a significant strain on the health systems of developed nations.<br />
*However, as an engaged and wealthy voting block, this demographic will actively vote for increased public spending on health services to support them in their greying years.<br />
*The economic strain of this massive senior citizen demographic will encourage developed nations to fast-track the testing and approval process for new drugs that may improve the overall physical and mental health of seniors, so that they remain well enough to lead independent lives outside the care of hospitals and nursing homes.<br />
*By the early 2030s, a range of treatments will emerge to stunt and later reverse the effects of aging. These treatments will be provided annually and over time will become affordable to the masses, resulting in longer average human lifespans and a new windfall for the pharmaceutical industry.<br />
*By 2050, the world population will rise above nine billion, over 80 percent of whom will live in cities. The high numbers and density of the future human population will result in more regular pandemic outbreaks that spread faster and are harder to cure.<br />
*The eventual widespread adoption of artificial intelligence (AI) and quantum computing within the pharmaceutical industry will lead to new, AI-assisted discoveries of drugs and treatments to cure a range of medical conditions. These AI pharmaceutical researchers will also result in new drugs and treatments being discovered at a far faster rate than is currently possible.</p>

Total patents held: 
48
Ranking List: 
664
Ranking List: 
2017 Quantumrun Global 1000
435
Ranking List: 
2017 Quantumrun US 500
81
Ranking List: 
2017 Quantumrun Silicon Valley 100
Market Revenue Country: 
Market country 
United States
Revenue from country 
1.00
Prod/Serv name revenue: 
Prod/Serv name: 
Nucynta
Prod/Serv revenue: 
189854000
Prod/Serv name: 
Gralise
Prod/Serv revenue: 
81054000
Prod/Serv name: 
Zipsor
Prod/Serv revenue: 
25705000
Founded: 
1995
Company Name: 
Depomed
Revenue: 
455897000
3y average revenue: 
396331667
Operating expenses: 
431388000
3y average expenses: 
326024000
Company profile data note: 
All company data collected from its 2016 annual report and other public sources. The accuracy of this data and the conclusions derived from them depend on this publicly accessible data. If a data point listed above is discovered to be inaccurate, Quantumrun will make the necessary corrections to this live page.
Global employee count: 
490
Number of domestic locations: 
1
Funds in reserve: 
117709000
Investment into R&D: 
32631000
create term: 
#664 | 2017 Quantumrun Global 1000
#435 | 2017 Quantumrun US 500
#81 | 2017 Quantumrun Silicon Valley 100

The Depomed, Inc. corporation is a U.S. based specialty pharmaceutical business, which chiefly deals in marketing of products for the treatment of pain, neurology, and illnesses relating to the central nervous system. The organization was originally founded in the year 1995 and has its headquarters based in Newark, California. This is a public trading company with numerous manufactured goods appropriated by the (FDA) or the United States Food and Drug Administration.

Home country:
United States
Sector:
Pharmaceuticals
Industry:
Pharmaceutical
Website:
Founded:
1995
Global employee count:
490

Financial Health

Revenue
$455,897,000 USD
3y average revenue
$396,331,667 USD
Operating expenses
$431,388,000 USD
3y average expenses
$326,024,000 USD
Funds in reserve
$117,709,000 USD
#1 Market country
United States
% of revenue from country #1
1%

Asset Performance

#1 Product/Service/Dept. name
Nucynta
#1 Product/Service revenue
$189,854,000 USD
#2 Product/Service/Dept. name
Gralise
#2 Product/Service revenue
$81,054,000 USD
#3 Product/Service/Dept. name
Zipsor
#3 Product/Service revenue
$25,705,000 USD

Innovation assets and Pipeline

Investment into R&D
$32,631,000 USD
Total patents held
48
All company data collected from its 2016 annual report and other public sources. The accuracy of this data and the conclusions derived from them depend on this publicly accessible data. If a data point listed above is discovered to be inaccurate, Quantumrun will make the necessary corrections to this live page.

Disruption Vulnerability

Belonging to the pharmaceuticals sector means this company will be affected directly and indirectly by a number of disruptive opportunities and challenges over the coming decades. While described in detail within Quantumrun’s special reports, these disruptive trends can be summarized along the following broad points:

*First off, the late 2020s will see the Silent and Boomer generations enter deep into their senior years. Representing nearly 30-40 per cent of the global population, this combined demographic will represent a significant strain on the health systems of developed nations.

*However, as an engaged and wealthy voting block, this demographic will actively vote for increased public spending on health services to support them in their greying years.

*The economic strain of this massive senior citizen demographic will encourage developed nations to fast-track the testing and approval process for new drugs that may improve the overall physical and mental health of seniors, so that they remain well enough to lead independent lives outside the care of hospitals and nursing homes.

*By the early 2030s, a range of treatments will emerge to stunt and later reverse the effects of aging. These treatments will be provided annually and over time will become affordable to the masses, resulting in longer average human lifespans and a new windfall for the pharmaceutical industry.

*By 2050, the world population will rise above nine billion, over 80 percent of whom will live in cities. The high numbers and density of the future human population will result in more regular pandemic outbreaks that spread faster and are harder to cure.

*The eventual widespread adoption of artificial intelligence (AI) and quantum computing within the pharmaceutical industry will lead to new, AI-assisted discoveries of drugs and treatments to cure a range of medical conditions. These AI pharmaceutical researchers will also result in new drugs and treatments being discovered at a far faster rate than is currently possible.